AR038350A1 - Carnitina en el tratamiento de la depresion geriatrica - Google Patents

Carnitina en el tratamiento de la depresion geriatrica

Info

Publication number
AR038350A1
AR038350A1 ARP030100356A ARP030100356A AR038350A1 AR 038350 A1 AR038350 A1 AR 038350A1 AR P030100356 A ARP030100356 A AR P030100356A AR P030100356 A ARP030100356 A AR P030100356A AR 038350 A1 AR038350 A1 AR 038350A1
Authority
AR
Argentina
Prior art keywords
carnitine
treatment
geriatric depression
depression
alkanoyl
Prior art date
Application number
ARP030100356A
Other languages
English (en)
Inventor
Jay W Pettegrew
Samuel Gershon
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR038350A1 publication Critical patent/AR038350A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Empleo de una carnitina seleccionada entre L-carnitina o alcanoil L-carnitina, preferentemente acetil L-carnitina, ó de una sal farmacéuticamente aceptable de la misma para la preparación de un medicamento útil para tratar la depresión en un sujeto, especialmente sujetos geriátricos. Los resultados obtenidos radican en la eficacia de la carnitina y la ausencia de los efectos secundarios significativos típicos de los bien conocidos antidepresivos.
ARP030100356A 2002-02-07 2003-02-05 Carnitina en el tratamiento de la depresion geriatrica AR038350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35432302P 2002-02-07 2002-02-07

Publications (1)

Publication Number Publication Date
AR038350A1 true AR038350A1 (es) 2005-01-12

Family

ID=27734357

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100356A AR038350A1 (es) 2002-02-07 2003-02-05 Carnitina en el tratamiento de la depresion geriatrica

Country Status (10)

Country Link
US (1) US20040009926A1 (es)
EP (1) EP1471904A1 (es)
JP (1) JP2005523269A (es)
KR (1) KR20040083471A (es)
AR (1) AR038350A1 (es)
AU (1) AU2003219511A1 (es)
CA (1) CA2469925A1 (es)
MX (1) MXPA04007506A (es)
PL (1) PL374082A1 (es)
WO (1) WO2003066041A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
DE602004022301D1 (de) 2003-05-29 2009-09-10 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
KR20130089158A (ko) 2010-06-16 2013-08-09 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. 신경 조직에서 신경발생을 증가시키기 위한 방법에 사용하기 위한 아세틸-카르니틴
SG11201703193XA (en) * 2014-10-28 2017-05-30 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
US11918336B2 (en) * 2019-02-19 2024-03-05 King Abdullah University Of Science And Technology Reduced feature generation for signal classification based on position weight matrix
AU2021272292A1 (en) 2020-05-15 2023-02-02 Alfasigma S.P.A. Composition comprising methylfolate
CA3238205A1 (en) * 2021-11-12 2023-05-19 Rajaram Samant A synergistic composition for activating intracellular secondary messenger(camp) pathway

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5879884A (en) * 1994-12-29 1999-03-09 Peroutka; Stephen J. Diagnosis of depression by linkage of a polymorphic marker to a segment of chromosome 19P13 bordered by D19S247 and D19S394
JP3425276B2 (ja) * 1995-08-11 2003-07-14 株式会社日立製作所 情報通知システム
JPH10143640A (ja) * 1996-11-15 1998-05-29 Nippon Lsi Card Kk 携帯コンピュータ及びそれを用いた情報管理システム並びにそれを用いた立体地図の作成方法
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism

Also Published As

Publication number Publication date
US20040009926A1 (en) 2004-01-15
MXPA04007506A (es) 2004-11-10
JP2005523269A (ja) 2005-08-04
CA2469925A1 (en) 2003-08-14
WO2003066041A1 (en) 2003-08-14
AU2003219511A1 (en) 2003-09-02
KR20040083471A (ko) 2004-10-02
PL374082A1 (en) 2005-09-19
EP1471904A1 (en) 2004-11-03

Similar Documents

Publication Publication Date Title
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
ECSP066516A (es) Formulaciones farmacéuticas, procedimientos y pautas de dosificación para el tratamiento y prevención de síndromes coronarios agudos
ES2531118T3 (es) Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia
AR090677A2 (es) Preparacion farmaceutica que contiene oxicodona y naloxona
HK1080447B (zh) 視黃醇衍生物、它們在治療癌症和增强其它細胞毒性劑功效中的應用
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
NO20034094L (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
IT1302365B1 (it) Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
AR028959A1 (es) Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
PT1185253E (pt) Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac
AR038350A1 (es) Carnitina en el tratamiento de la depresion geriatrica
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
DK1265577T3 (da) Medicinsk eller dentalmedicinsk behandlingsstol
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
AR024981A1 (es) Composicion para la prevencion y el tratamiento de las disfunciones y enfermedades del rinon
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
DE60301862D1 (de) Kombinationsbehandlung bei akutem myokardinfarkt

Legal Events

Date Code Title Description
FB Suspension of granting procedure